請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15745
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 沈麗娟(Li-Juan Shen) | |
dc.contributor.author | Jyun-wei Kang | en |
dc.contributor.author | 康竣崴 | zh_TW |
dc.date.accessioned | 2021-06-07T17:51:12Z | - |
dc.date.copyright | 2013-03-04 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-10-02 | |
dc.identifier.citation | [1] S. Stolnik, K. Shakesheff, Formulations for delivery of therapeutic proteins, Biotechnol Lett 31 (2009) 1-11.
[2] F.G. Banting, C.H. Best, J.B. Collip, W.R. Campbell, A.A. Fletcher, Pancreatic Extracts in the Treatment of Diabetes Mellitus, Can Med Assoc J 12 (1922) 141-146. [3] L.M. Souza, T.C. Boone, J. Gabrilove, P.H. Lai, K.M. Zsebo, D.C. Murdock, V.R. Chazin, J. Bruszewski, H. Lu, K.K. Chen, et al., Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells, Science 232 (1986) 61-65. [4] W. Jelkmann, Erythropoietin after a century of research: younger than ever, Eur J Haematol 78 (2007) 183-205. [5] K.G. Saag, E. Shane, S. Boonen, F. Marin, D.W. Donley, K.A. Taylor, G.P. Dalsky, R. Marcus, Teriparatide or alendronate in glucocorticoid-induced osteoporosis, N Engl J Med 357 (2007) 2028-2039. [6] C.A. Hudis, Trastuzumab--mechanism of action and use in clinical practice, N Engl J Med 357 (2007) 39-51. [7] N. Scheinfeld, Adalimumab (HUMIRA): a review, J Drugs Dermatol 2 (2003) 375-377. [8] F.R. Salemme, Structure and function of cytochromes c, Annu Rev Biochem 46 (1977) 299-329. [9] G. Selivanova, V. Iotsova, I. Okan, M. Fritsche, M. Strom, B. Groner, R.C. Grafstrom, K.G. Wiman, Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain, Nat Med 3 (1997) 632-638. [10] J. Turkson, D. Ryan, J.S. Kim, Y. Zhang, Z. Chen, E. Haura, A. Laudano, S. Sebti, A.D. Hamilton, R. Jove, Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation, J Biol Chem 276 (2001) 45443-45455. [11] Y. Li, Y. Mao, R.V. Rosal, R.D. Dinnen, A.C. Williams, P.W. Brandt-Rauf, R.L. Fine, Selective induction of apoptosis through the FADD/caspase-8 pathway by a p53 c-terminal peptide in human pre-malignant and malignant cells, Int J Cancer 115 (2005) 55-64. [12] D. Araki, K. Takayama, M. Inoue, T. Watanabe, H. Kumon, S. Futaki, H. Matsui, K. Tomizawa, Cell-penetrating D-isomer peptides of p53 C-terminus: long-term inhibitory effect on the growth of bladder cancer, Urology 75 (2010) 813-819. [13] M. Tan, K.H. Lan, J. Yao, C.H. Lu, M. Sun, C.L. Neal, J. Lu, D. Yu, Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide, Cancer Res 66 (2006) 3764-3772. [14] M.P. Barnes, W.C. Shen, Disulfide and thioether linked cytochrome c-oligoarginine conjugates in HeLa cells, Int J Pharm 369 (2009) 79-84. [15] L.A. Kueltzo, C.R. Middaugh, Nonclassical transport proteins and peptides: an alternative to classical macromolecule delivery systems, J Pharm Sci 92 (2003) 1754-1772. [16] H. Li, Z.M. Qian, Transferrin/transferrin receptor-mediated drug delivery, Med Res Rev 22 (2002) 225-250. [17] C.Q. Xia, J. Wang, W.C. Shen, Hypoglycemic effect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats, J Pharmacol Exp Ther 295 (2000) 594-600. [18] G. Sahay, D.Y. Alakhova, A.V. Kabanov, Endocytosis of nanomedicines, J Control Release 145 (2010) 182-195. [19] C.S. Paulo, R. Pires das Neves, L.S. Ferreira, Nanoparticles for intracellular-targeted drug delivery, Nanotechnology 22 (2011) 494002. [20] L. Hasadsri, J. Kreuter, H. Hattori, T. Iwasaki, J.M. George, Functional protein delivery into neurons using polymeric nanoparticles, J Biol Chem 284 (2009) 6972-6981. [21] F. Heitz, M.C. Morris, G. Divita, Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics, Br J Pharmacol 157 (2009) 195-206. [22] L.N. Patel, J.L. Zaro, W.C. Shen, Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives, Pharm Res 24 (2007) 1977-1992. [23] F. Madani, S. Lindberg, U. Langel, S. Futaki, A. Graslund, Mechanisms of cellular uptake of cell-penetrating peptides, J Biophys 2011 (2011) 414729. [24] A.D. Frankel, C.O. Pabo, Cellular uptake of the tat protein from human immunodeficiency virus, Cell 55 (1988) 1189-1193. [25] E. Vives, P. Brodin, B. Lebleu, A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus, J Biol Chem 272 (1997) 16010-16017. [26] A. Joliot, C. Pernelle, H. Deagostini-Bazin, A. Prochiantz, Antennapedia homeobox peptide regulates neural morphogenesis, Proc Natl Acad Sci U S A 88 (1991) 1864-1868. [27] D. Derossi, A.H. Joliot, G. Chassaing, A. Prochiantz, The third helix of the Antennapedia homeodomain translocates through biological membranes, J Biol Chem 269 (1994) 10444-10450. [28] S.B. Fonseca, M.P. Pereira, S.O. Kelley, Recent advances in the use of cell-penetrating peptides for medical and biological applications, Adv Drug Deliv Rev 61 (2009) 953-964. [29] M. Zorko, U. Langel, Cell-penetrating peptides: mechanism and kinetics of cargo delivery, Adv Drug Deliv Rev 57 (2005) 529-545. [30] A. Elmquist, M. Lindgren, T. Bartfai, U. Langel, VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions, Exp Cell Res 269 (2001) 237-244. [31] M.C. Morris, P. Vidal, L. Chaloin, F. Heitz, G. Divita, A new peptide vector for efficient delivery of oligonucleotides into mammalian cells, Nucleic Acids Res 25 (1997) 2730-2736. [32] M. Pooga, M. Hallbrink, M. Zorko, U. Langel, Cell penetration by transportan, FASEB J 12 (1998) 67-77. [33] J. Oehlke, A. Scheller, B. Wiesner, E. Krause, M. Beyermann, E. Klauschenz, M. Melzig, M. Bienert, Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically, Biochim Biophys Acta 1414 (1998) 127-139. [34] S. Futaki, T. Suzuki, W. Ohashi, T. Yagami, S. Tanaka, K. Ueda, Y. Sugiura, Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery, J Biol Chem 276 (2001) 5836-5840. [35] S. El-Andaloussi, H.J. Johansson, T. Holm, U. Langel, A novel cell-penetrating peptide, M918, for efficient delivery of proteins and peptide nucleic acids, Mol Ther 15 (2007) 1820-1826. [36] S.T. Henriques, M.A. Castanho, Consequences of nonlytic membrane perturbation to the translocation of the cell penetrating peptide pep-1 in lipidic vesicles, Biochemistry 43 (2004) 9716-9724. [37] H. Raagel, P. Saalik, M. Pooga, Peptide-mediated protein delivery-which pathways are penetrable?, Biochim Biophys Acta 1798 (2010) 2240-2248. [38] G. Ter-Avetisyan, G. Tunnemann, D. Nowak, M. Nitschke, A. Herrmann, M. Drab, M.C. Cardoso, Cell entry of arginine-rich peptides is independent of endocytosis, J Biol Chem 284 (2009) 3370-3378. [39] F. Simeoni, M.C. Morris, F. Heitz, G. Divita, Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells, Nucleic Acids Res 31 (2003) 2717-2724. [40] S. Deshayes, M.C. Morris, G. Divita, F. Heitz, Interactions of amphipathic CPPs with model membranes, Biochim Biophys Acta 1758 (2006) 328-335. [41] J.L. Zaro, W.C. Shen, Evidence that membrane transduction of oligoarginine does not require vesicle formation, Exp Cell Res 307 (2005) 164-173. [42] J.L. Zaro, W.C. Shen, Cytosolic delivery of a p16-peptide oligoarginine conjugate for inhibiting proliferation of MCF7 cells, J Control Release 108 (2005) 409-417. [43] J.A. Swanson, C. Watts, Macropinocytosis, Trends Cell Biol 5 (1995) 424-428. [44] T.F. Roth, K.R. Porter, Yolk Protein Uptake in the Oocyte of the Mosquito Aedes Aegypti. L, J Cell Biol 20 (1964) 313-332. [45] K.G. Rothberg, J.E. Heuser, W.C. Donzell, Y.S. Ying, J.R. Glenney, R.G. Anderson, Caveolin, a protein component of caveolae membrane coats, Cell 68 (1992) 673-682. [46] O.O. Glebov, N.A. Bright, B.J. Nichols, Flotillin-1 defines a clathrin-independent endocytic pathway in mammalian cells, Nat Cell Biol 8 (2006) 46-54. [47] G.J. Doherty, H.T. McMahon, Mechanisms of endocytosis, Annu Rev Biochem 78 (2009) 857-902. [48] S. Falcone, E. Cocucci, P. Podini, T. Kirchhausen, E. Clementi, J. Meldolesi, Macropinocytosis: regulated coordination of endocytic and exocytic membrane traffic events, J Cell Sci 119 (2006) 4758-4769. [49] M. Lakadamyali, M.J. Rust, X. Zhuang, Ligands for clathrin-mediated endocytosis are differentially sorted into distinct populations of early endosomes, Cell 124 (2006) 997-1009. [50] R. Zoncu, R.M. Perera, D.M. Balkin, M. Pirruccello, D. Toomre, P. De Camilli, A phosphoinositide switch controls the maturation and signaling properties of APPL endosomes, Cell 136 (2009) 1110-1121. [51] I.R. Nabi, P.U. Le, Caveolae/raft-dependent endocytosis, J Cell Biol 161 (2003) 673-677. [52] R.G. Parton, A.A. Richards, Lipid rafts and caveolae as portals for endocytosis: new insights and common mechanisms, Traffic 4 (2003) 724-738. [53] L. Pelkmans, T. Burli, M. Zerial, A. Helenius, Caveolin-stabilized membrane domains as multifunctional transport and sorting devices in endocytic membrane traffic, Cell 118 (2004) 767-780. [54] M. Frick, N.A. Bright, K. Riento, A. Bray, C. Merrified, B.J. Nichols, Coassembly of flotillins induces formation of membrane microdomains, membrane curvature, and vesicle budding, Curr Biol 17 (2007) 1151-1156. [55] C.K. Payne, S.A. Jones, C. Chen, X. Zhuang, Internalization and trafficking of cell surface proteoglycans and proteoglycan-binding ligands, Traffic 8 (2007) 389-401. [56] M. Kirkham, R.G. Parton, Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers, Biochim Biophys Acta 1746 (2005) 349-363. [57] S. Mayor, R.E. Pagano, Pathways of clathrin-independent endocytosis, Nat Rev Mol Cell Biol 8 (2007) 603-612. [58] G. Drin, S. Cottin, E. Blanc, A.R. Rees, J. Temsamani, Studies on the internalization mechanism of cationic cell-penetrating peptides, J Biol Chem 278 (2003) 31192-31201. [59] J.P. Richard, K. Melikov, E. Vives, C. Ramos, B. Verbeure, M.J. Gait, L.V. Chernomordik, B. Lebleu, Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake, J Biol Chem 278 (2003) 585-590. [60] P. Saalik, A. Elmquist, M. Hansen, K. Padari, K. Saar, K. Viht, U. Langel, M. Pooga, Protein cargo delivery properties of cell-penetrating peptides. A comparative study, Bioconjug Chem 15 (2004) 1246-1253. [61] S.W. Jones, R. Christison, K. Bundell, C.J. Voyce, S.M. Brockbank, P. Newham, M.A. Lindsay, Characterisation of cell-penetrating peptide-mediated peptide delivery, Br J Pharmacol 145 (2005) 1093-1102. [62] P. Saalik, K. Padari, A. Niinep, A. Lorents, M. Hansen, E. Jokitalo, U. Langel, M. Pooga, Protein delivery with transportans is mediated by caveolae rather than flotillin-dependent pathways, Bioconjug Chem 20 (2009) 877-887. [63] I.M. Kaplan, J.S. Wadia, S.F. Dowdy, Cationic TAT peptide transduction domain enters cells by macropinocytosis, J Control Release 102 (2005) 247-253. [64] J.P. Richard, K. Melikov, H. Brooks, P. Prevot, B. Lebleu, L.V. Chernomordik, Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors, J Biol Chem 280 (2005) 15300-15306. [65] A. Fittipaldi, A. Ferrari, M. Zoppe, C. Arcangeli, V. Pellegrini, F. Beltram, M. Giacca, Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins, J Biol Chem 278 (2003) 34141-34149. [66] P. Lundin, H. Johansson, P. Guterstam, T. Holm, M. Hansen, U. Langel, E.L.A. S, Distinct uptake routes of cell-penetrating peptide conjugates, Bioconjug Chem 19 (2008) 2535-2542. [67] F. Duchardt, M. Fotin-Mleczek, H. Schwarz, R. Fischer, R. Brock, A comprehensive model for the cellular uptake of cationic cell-penetrating peptides, Traffic 8 (2007) 848-866. [68] J.L. Zaro, W.C. Shen, Quantitative comparison of membrane transduction and endocytosis of oligopeptides, Biochem Biophys Res Commun 307 (2003) 241-247. [69] Y. Takechi, H. Tanaka, H. Kitayama, H. Yoshii, M. Tanaka, H. Saito, Comparative study on the interaction of cell-penetrating polycationic polymers with lipid membranes, Chem Phys Lipids 165 (2012) 51-58. [70] J. Mueller, I. Kretzschmar, R. Volkmer, P. Boisguerin, Comparison of cellular uptake using 22 CPPs in 4 different cell lines, Bioconjug Chem 19 (2008) 2363-2374. [71] M. Tyagi, M. Rusnati, M. Presta, M. Giacca, Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans, J Biol Chem 276 (2001) 3254-3261. [72] M. Silhol, M. Tyagi, M. Giacca, B. Lebleu, E. Vives, Different mechanisms for cellular internalization of the HIV-1 Tat-derived cell penetrating peptide and recombinant proteins fused to Tat, Eur J Biochem 269 (2002) 494-501. [73] S.J. Kwon, K. Han, S. Jung, J.E. Lee, S. Park, Y.P. Cheon, H.J. Lim, Transduction of the MPG-tagged fusion protein into mammalian cells and oocytes depends on amiloride-sensitive endocytic pathway, BMC Biotechnol 9 (2009) 73. [74] G. Tunnemann, R.M. Martin, S. Haupt, C. Patsch, F. Edenhofer, M.C. Cardoso, Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells, FASEB J 20 (2006) 1775-1784. [75] S. Sandgren, F. Cheng, M. Belting, Nuclear targeting of macromolecular polyanions by an HIV-Tat derived peptide. Role for cell-surface proteoglycans, J Biol Chem 277 (2002) 38877-38883. [76] J.C. Mai, H. Shen, S.C. Watkins, T. Cheng, P.D. Robbins, Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate, J Biol Chem 277 (2002) 30208-30218. [77] M. Lindgren, K. Rosenthal-Aizman, K. Saar, E. Eiriksdottir, Y. Jiang, M. Sassian, P. Ostlund, M. Hallbrink, U. Langel, Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide, Biochem Pharmacol 71 (2006) 416-425. [78] E.A. Dubikovskaya, S.H. Thorne, T.H. Pillow, C.H. Contag, P.A. Wender, Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters, Proc Natl Acad Sci U S A 105 (2008) 12128-12133. [79] A. Muratovska, M.R. Eccles, Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells, FEBS Lett 558 (2004) 63-68. [80] M.C. Morris, L. Chaloin, J. Mery, F. Heitz, G. Divita, A novel potent strategy for gene delivery using a single peptide vector as a carrier, Nucleic Acids Res 27 (1999) 3510-3517. [81] P.B. Senatus, Y. Li, C. Mandigo, G. Nichols, G. Moise, Y. Mao, M.D. Brown, R.C. Anderson, A.T. Parsa, P.W. Brandt-Rauf, J.N. Bruce, R.L. Fine, Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-terminal peptide, Mol Cancer Ther 5 (2006) 20-28. [82] E.L. Snyder, B.R. Meade, C.C. Saenz, S.F. Dowdy, Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide, PLoS Biol 2 (2004) E36. [83] J.B. Rothbard, S. Garlington, Q. Lin, T. Kirschberg, E. Kreider, P.L. McGrane, P.A. Wender, P.A. Khavari, Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation, Nat Med 6 (2000) 1253-1257. [84] K. Inagaki, L. Chen, F. Ikeno, F.H. Lee, K. Imahashi, D.M. Bouley, M. Rezaee, P.G. Yock, E. Murphy, D. Mochly-Rosen, Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo, Circulation 108 (2003) 2304-2307. [85] E. Bates, C. Bode, M. Costa, C.M. Gibson, C. Granger, C. Green, K. Grimes, R. Harrington, K. Huber, N. Kleiman, D. Mochly-Rosen, M. Roe, Z. Sadowski, S. Solomon, P. Widimsky, Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction, Circulation 117 (2008) 886-896. [86] G. Milano, S. Morel, C. Bonny, M. Samaja, L.K. von Segesser, P. Nicod, G. Vassalli, A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo, Am J Physiol Heart Circ Physiol 292 (2007) H1828-1835. [87] D. Michel-Monigadon, C. Bonny, L. Hirt, c-Jun N-terminal kinase pathway inhibition in intracerebral hemorrhage, Cerebrovasc Dis 29 (2010) 564-570. [88] S.R. Schwarze, A. Ho, A. Vocero-Akbani, S.F. Dowdy, In vivo protein transduction: delivery of a biologically active protein into the mouse, Science 285 (1999) 1569-1572. [89] D. Sarko, B. Beijer, R. Garcia Boy, E.M. Nothelfer, K. Leotta, M. Eisenhut, A. Altmann, U. Haberkorn, W. Mier, The pharmacokinetics of cell-penetrating peptides, Mol Pharm 7 (2010) 2224-2231. [90] S. El-Andaloussi, P. Jarver, H.J. Johansson, U. Langel, Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study, Biochem J 407 (2007) 285-292. [91] T. Sugita, T. Yoshikawa, Y. Mukai, N. Yamanada, S. Imai, K. Nagano, Y. Yoshida, H. Shibata, Y. Yoshioka, S. Nakagawa, H. Kamada, S.I. Tsunoda, Y. Tsutsumi, Comparative study on transduction and toxicity of protein transduction domains, Br J Pharmacol 153 (2008) 1143-1152. [92] W.P. Verdurmen, R. Brock, Biological responses towards cationic peptides and drug carriers, Trends Pharmacol Sci 32 (2011) 116-124. [93] K. Saar, M. Lindgren, M. Hansen, E. Eiriksdottir, Y. Jiang, K. Rosenthal-Aizman, M. Sassian, U. Langel, Cell-penetrating peptides: a comparative membrane toxicity study, Anal Biochem 345 (2005) 55-65. [94] W.P. Verdurmen, M. Thanos, I.R. Ruttekolk, E. Gulbins, R. Brock, Cationic cell-penetrating peptides induce ceramide formation via acid sphingomyelinase: implications for uptake, J Control Release 147 (2010) 171-179. [95] K. Kilk, R. Mahlapuu, U. Soomets, U. Langel, Analysis of in vitro toxicity of five cell-penetrating peptides by metabolic profiling, Toxicology 265 (2009) 87-95. [96] M. Fotin-Mleczek, S. Welte, O. Mader, F. Duchardt, R. Fischer, H. Hufnagel, P. Scheurich, R. Brock, Cationic cell-penetrating peptides interfere with TNF signalling by induction of TNF receptor internalization, J Cell Sci 118 (2005) 3339-3351. [97] K. Pethe, S. Alonso, F. Biet, G. Delogu, M.J. Brennan, C. Locht, F.D. Menozzi, The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination, Nature 412 (2001) 190-194. [98] F.D. Menozzi, V.M. Reddy, D. Cayet, D. Raze, A.S. Debrie, M.P. Dehouck, R. Cecchelli, C. Locht, Mycobacterium tuberculosis heparin-binding haemagglutinin adhesin (HBHA) triggers receptor-mediated transcytosis without altering the integrity of tight junctions, Microbes Infect 8 (2006) 1-9. [99] F.D. Menozzi, J.H. Rouse, M. Alavi, M. Laude-Sharp, J. Muller, R. Bischoff, M.J. Brennan, C. Locht, Identification of a heparin-binding hemagglutinin present in mycobacteria, J Exp Med 184 (1996) 993-1001. [100] G. Delogu, M.J. Brennan, Functional domains present in the mycobacterial hemagglutinin, HBHA, J Bacteriol 181 (1999) 7464-7469. [101] C. Esposito, M.V. Pethoukov, D.I. Svergun, A. Ruggiero, C. Pedone, E. Pedone, R. Berisio, Evidence for an elongated dimeric structure of heparin-binding hemagglutinin from Mycobacterium tuberculosis, J Bacteriol 190 (2008) 4749-4753. [102] C.S. de Lima, M.A. Marques, A.S. Debrie, E.C. Almeida, C.A. Silva, P.J. Brennan, E.N. Sarno, F.D. Menozzi, M.C. Pessolani, Heparin-binding hemagglutinin (HBHA) of Mycobacterium leprae is expressed during infection and enhances bacterial adherence to epithelial cells, FEMS Microbiol Lett 292 (2009) 162-169. [103] K. Pethe, M. Aumercier, E. Fort, C. Gatot, C. Locht, F.D. Menozzi, Characterization of the heparin-binding site of the mycobacterial heparin-binding hemagglutinin adhesin, J Biol Chem 275 (2000) 14273-14280. [104] 鄭如辰,研究肝素結合凝血附著素相關胜肽之穿胞運輸性質,National Taiwan University (2009) [105] 邱予芹,研究肝素結合凝血附著素c之蛋白質運送能力,National Taiwan University (2010) [106] 研究D-肝素結合凝血附著素c(D-HBHAc)胜肽之安定性及蛋白質運輸能力,National Taiwan University (2011) [107] O. Shimomura, F.H. Johnson, Y. Saiga, Extraction, purification and properties of aequorin, a bioluminescent protein from the luminous hydromedusan, Aequorea, J Cell Comp Physiol 59 (1962) 223-239. [108] H. Morise, O. Shimomura, F.H. Johnson, J. Winant, Intermolecular energy transfer in the bioluminescent system of Aequorea, Biochemistry 13 (1974) 2656-2662. [109] M. Chalfie, Y. Tu, G. Euskirchen, W.W. Ward, D.C. Prasher, Green fluorescent protein as a marker for gene expression, Science 263 (1994) 802-805. [110] S. Inouye, F.I. Tsuji, Aequorea green fluorescent protein. Expression of the gene and fluorescence characteristics of the recombinant protein, FEBS Lett 341 (1994) 277-280. [111] R. Heim, A.B. Cubitt, R.Y. Tsien, Improved green fluorescence, Nature 373 (1995) 663-664. [112] R.Y. Tsien, The green fluorescent protein, Annu Rev Biochem 67 (1998) 509-544. [113] N.C. Shaner, P.A. Steinbach, R.Y. Tsien, A guide to choosing fluorescent proteins, Nat Methods 2 (2005) 905-909. [114] D.M. Chudakov, M.V. Matz, S. Lukyanov, K.A. Lukyanov, Fluorescent proteins and their applications in imaging living cells and tissues, Physiol Rev 90 (2010) 1103-1163. [115] F. Yang, L.G. Moss, G.N. Phillips, Jr., The molecular structure of green fluorescent protein, Nat Biotechnol 14 (1996) 1246-1251. [116] M. Ormo, A.B. Cubitt, K. Kallio, L.A. Gross, R.Y. Tsien, S.J. Remington, Crystal structure of the Aequorea victoria green fluorescent protein, Science 273 (1996) 1392-1395. [117] A. Ferrari, V. Pellegrini, C. Arcangeli, A. Fittipaldi, M. Giacca, F. Beltram, Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time, Mol Ther 8 (2003) 284-294. [118] K. Nishi, K. Saigo, Cellular internalization of green fluorescent protein fused with herpes simplex virus protein VP22 via a lipid raft-mediated endocytic pathway independent of caveolae and Rho family GTPases but dependent on dynamin and Arf6, J Biol Chem 282 (2007) 27503-27517. [119] R. Rothe, L. Liguori, A. Villegas-Mendez, B. Marques, D. Grunwald, E. Drouet, J.L. Lenormand, Characterization of the cell-penetrating properties of the Epstein-Barr virus ZEBRA trans-activator, J Biol Chem 285 (2010) 20224-20233. [120] J. Porath, J. Carlsson, I. Olsson, G. Belfrage, Metal chelate affinity chromatography, a new approach to protein fractionation, Nature 258 (1975) 598-599. [121] E. Hochuli, H. Dobeli, A. Schacher, New metal chelate adsorbent selective for proteins and peptides containing neighbouring histidine residues, J Chromatogr 411 (1987) 177-184. [122] E. Hochuli, W. Bannwarth, H. Dobeli, R. Gentz, D. Stuber, Genetic Approach to Facilitate Purification of Recombinant Proteins with a Novel Metal Chelate Adsorbent, Bio-Technology 6 (1988) 1321-1325. [123] D.M. Morgan, Tetrazolium (MTT) assay for cellular viability and activity, Methods Mol Biol 79 (1998) 179-183. [124] A.K. Varkouhi, M. Scholte, G. Storm, H.J. Haisma, Endosomal escape pathways for delivery of biologicals, J Control Release 151 (2011) 220-228. [125] H.A. de Boer, L.J. Comstock, M. Vasser, The tac promoter: a functional hybrid derived from the trp and lac promoters, Proc Natl Acad Sci U S A 80 (1983) 21-25. [126] E. Vives, J. Schmidt, A. Pelegrin, Cell-penetrating and cell-targeting peptides in drug delivery, Biochim Biophys Acta 1786 (2008) 126-138. [127] B.S. Weeks, D.M. Lieberman, B. Johnson, E. Roque, M. Green, P. Loewenstein, E.H. Oldfield, H.K. Kleinman, Neurotoxicity of the human immunodeficiency virus type 1 tat transactivator to PC12 cells requires the Tat amino acid 49-58 basic domain, J Neurosci Res 42 (1995) 34-40. [128] F.T. Mu, J.M. Callaghan, O. Steele-Mortimer, H. Stenmark, R.G. Parton, P.L. Campbell, J. McCluskey, J.P. Yeo, E.P. Tock, B.H. Toh, EEA1, an early endosome-associated protein. EEA1 is a conserved alpha-helical peripheral membrane protein flanked by cysteine 'fingers' and contains a calmodulin-binding IQ motif, J Biol Chem 270 (1995) 13503-13511. [129] H. Raagel, P. Saalik, M. Hansen, U. Langel, M. Pooga, CPP-protein constructs induce a population of non-acidic vesicles during trafficking through endo-lysosomal pathway, J Control Release 139 (2009) 108-117. [130] M.M. Fretz, N.A. Penning, S. Al-Taei, S. Futaki, T. Takeuchi, I. Nakase, G. Storm, A.T. Jones, Temperature-, concentration- and cholesterol-dependent translocation of L- and D-octa-arginine across the plasma and nuclear membrane of CD34+ leukaemia cells, Biochem J 403 (2007) 335-342. [131] A.I. Ivanov, Pharmacological inhibition of endocytic pathways: is it specific enough to be useful?, Methods Mol Biol 440 (2008) 15-33. [132] D. Derossi, S. Calvet, A. Trembleau, A. Brunissen, G. Chassaing, A. Prochiantz, Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent, J Biol Chem 271 (1996) 18188-18193. [133] P.A. Wender, D.J. Mitchell, K. Pattabiraman, E.T. Pelkey, L. Steinman, J.B. Rothbard, The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters, Proc Natl Acad Sci U S A 97 (2000) 13003-13008. [134] H. Binder, G. Lindblom, Charge-dependent translocation of the Trojan peptide penetratin across lipid membranes, Biophys J 85 (2003) 982-995. [135] D. Terrone, S.L. Sang, L. Roudaia, J.R. Silvius, Penetratin and related cell-penetrating cationic peptides can translocate across lipid bilayers in the presence of a transbilayer potential, Biochemistry 42 (2003) 13787-13799. [136] H. Yezid, K. Konate, S. Debaisieux, A. Bonhoure, B. Beaumelle, Mechanism for HIV-1 Tat insertion into the endosome membrane, J Biol Chem 284 (2009) 22736-22746. [137] X. Han, J.H. Bushweller, D.S. Cafiso, L.K. Tamm, Membrane structure and fusion-triggering conformational change of the fusion domain from influenza hemagglutinin, Nat Struct Biol 8 (2001) 715-720. [138] J.S. Wadia, R.V. Stan, S.F. Dowdy, Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis, Nat Med 10 (2004) 310-315. [139] H. Michiue, K. Tomizawa, F.Y. Wei, M. Matsushita, Y.F. Lu, T. Ichikawa, T. Tamiya, I. Date, H. Matsui, The NH2 terminus of influenza virus hemagglutinin-2 subunit peptides enhances the antitumor potency of polyarginine-mediated p53 protein transduction, J Biol Chem 280 (2005) 8285-8289. [140] A.A. Pakhomov, V.I. Martynov, GFP family: structural insights into spectral tuning, Chem Biol 15 (2008) 755-764. [141] G. Elliott, P. O'Hare, Intercellular trafficking and protein delivery by a herpesvirus structural protein, Cell 88 (1997) 223-233. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15745 | - |
dc.description.abstract | 肝素結合凝血附著素 (heparin-binding haemaglutinin adhesin,HBHA) 是一個源自於分枝桿菌的表面抗原蛋白,其中C端的片段負責著HBHA黏附於肺部表皮細胞與肺外擴散的功能,此C端的片段主要是由兩個片段重複排列組合而成:KKAAPA (R1) 和KKAAAKK (R2) ,本實驗室發現以1R1+2R2之25個胺基酸組合的胜肽,HBHAc,在人類肺臟上皮癌細胞 (A549) 與人類結腸癌細胞 (Caco-2) 具有極佳的結合、攝取與穿胞之能力。為了更進一步了解HBHAc作為蛋白質載體的能力,本研究以綠色螢光蛋白 (EGFP) 作為模式蛋白,利用EGFP的螢光活性來評估HBHAc遞送蛋白質進入細胞的能力,並進一步研究其在細胞內的分布途徑與被細胞攝取的相關機轉。
本研究利用E. coli BL21大量表現帶有histidine-tag的EGFP與HBHAc-EGFP重組蛋白後以nickel-nitrilotriactic acid (Ni-NTA) 作為親合性的材料來進行純化。以HepG2人類肝癌細胞株為本研究中體外試驗的給藥目標,首先,以MTT assay來研究EGFP或是HBHAc-EGFP重組蛋白是否會影響細胞存活率,接著,再以流式細胞儀與共軛焦螢光顯微鏡來分析並觀察HBHAc-EGFP進入細胞的效率,確認HBHAc-EGFP能有效地進入細胞後則進一步以免疫螢光分析法來觀察HBHAc-EGFP在細胞內的分布位置,並且藉由給予chloroquine來研究HBHAc-EGFP在細胞內是否會經由endolysosomal pathway,最後,利用溫度、胞吞作用抑制劑與膜作用競爭劑對HBHAc-EGFP進入細胞的影響來進一步研究HBHAc-EGFP的細胞攝取機轉。 研究結果顯示,本研究的純化方法可以有效地純化出高純度的EGFP與HBHAc-EGFP重組蛋白。首先,在有效的遞送濃度下,HBHAc-EGFP並不會對細胞的存活率造成明顯的影響;接著,在進入細胞的效率分析方面,以1 μM的給藥濃度培養1小時後,HBHAc-EGFP可進入超過95%的細胞,EGFP則是只有進入約3%左右的細胞,且投予HBHAc-EGFP的細胞平均螢光強度為投予EGFP的細胞平均螢光強度的10倍以上;另外,在1小時的給藥時間內,HBHAc-EGFP進入細胞的效率與給藥劑量成正相關性,細胞平均螢光強度亦與給藥時間成正相關性,在共軛焦螢光顯微鏡的結果中亦可觀察到此現象,但是在給藥2小時後,不論是在高濃度或是低濃度下,細胞平均螢光強度均有明顯下降的趨勢。 在細胞內的分布途徑方面,以共軛焦螢光顯微鏡可觀察到HBHAc-EGFP分布於細胞內的囊泡中,與early endosome antigen-1有明顯的交集,但未觀察到HBHAc-EGFP與caveolin-1有交集的現象;另外,chloroquine的給予可使已進入細胞內的HBHAc-EGFP在12小時後仍維持與起始時間相當的螢光強度,而未給予chloroquine的細胞平均螢光強度在12個小時後則是下降至原本的10%左右;以共軛焦螢光顯微鏡亦可觀察到給予chloroquine的組別在停藥後3小時細胞内仍有明顯的螢光訊號,並且呈現大範圍的聚集,而未給予chloroquine的組別在停藥後3小時細胞内則是幾乎無法偵測到螢光訊號。 在細胞的攝取機轉方面,在16℃和4℃的條件下,不論給藥劑量的高低,HBHAc-EGFP的相對細胞攝取量均有非常顯著的下降;不同的胞吞作用抑制劑對HBHAc-EGFP進入細胞均有不同程度的抑制效果,而其中抑制程度最高的為chlorpromazine,當給予濃度至20 μg/mL時會有40%左右的抑制效果;膜作用競爭劑 (heparin、dextran sulfate) 對HBHAc-EGFP的細胞攝取均有顯著的抑制效果,當給予濃度至30 μg/mL會有90%左右的抑制效果。 綜合以上研究結果,可推測HBHAc-EGFP會先與細胞膜上的醣蛋白產生作用而黏附於細胞膜上,主要經由clathrin-mediated endocytosis進入細胞,進入細胞後會分布於endosome中,並且經由endolysosomal pathway被降解,而此機制與HBHAc本身進入細胞的機制不同,過去的結果顯示,HBHAc可能會利用direct tranduction或是lipid-raft mediated endocytosis的途徑進入細胞。另外,膜作用競爭劑對HBHAc-EGFP進入細胞的抑制效果較HBHAc來得顯著。 HBHAc能有效地將EGFP遞送進入細胞内並維持EGFP的活性,並且在有效的遞送濃度內不會對細胞造成明顯的毒性,但由於HBHAc-EGFP主要會經由endolysosomal pathway被降解,因此,若要作為有效的蛋白質藥物遞送載體,可能必須配合適當的endosome escape策略使蛋白質藥物在細胞內得以發揮最大的效用。 | zh_TW |
dc.description.abstract | Heparin-binding hemagglutinin adhesin (HBHA) is a 28 kDa heparin-binding mycobacterial protein expressed on the surface of Mycobacterium tuberculosis. The C-terminal domain of HBHA dominates adherence to epithelial cells and mediates extra-pulmonary dissemination. The C-terminal region is identified with two repeated motifs : KKAAPA (R1) and KKAAAKK (R2) . In our previous study, one peptide with the sequence of 1R1+2R2 named HBHAc showed the good ability of cell binding, uptake and transport in A549 and Caco-2 cell line. To understandthe the ability and mechanism of HBHAc in protein delivery, enhanced green fluorescence protein (EGFP) fused with HBHAc was used in this study.
Fisrt, we used nickel-nitrilotriactic acid (Ni-NTA) to purify histidine tagged EGFP or HBHAc-EGFP overexpressed in E. coli BL21. The human hepatocellular carcinoma cell line, HepG2, was used as an in vitro model. We utilized MTT assay to examine whether the cell viability is affected by recombinant EGFP and HBHAc-EGFP, respectively. We further analyzed the uptake efficiency of HBHAc-EGFP by flow cytometry and confocal microscopy. Immunofluorescence assay was used to investigate the intracellular distribution of HBHAc-EGFP. We also applied chloroquine to investigate the escape of HBHAc-EGFP from endolysosomal pathway. The cellular uptake mechanism of HBHAc-EGFP was studied by studying the effect of different temperature, endocytosis inhibitors, and membrane interaction competitors. Based on SDS-PAGE analysis, EGFP and HBHAc-EGFP recombinant protein was obtained with high purity after purification. No cytotoxicity of both protiens was found in HepG2 cells after 24 h incubation at concentration up to 10 μM. Based on the results of flow cytometry, HBHAc-EGFP efficienctly entered into above 95% of total cells and the mean fluorescence intensity was 25.43 a.u. after 1 h incubation at 1 μM concentration. On the contrary, EGFP only entered into 2% of total cells and the mean fluorescence intensity was 2.97 a.u. under the same condition. Based on the confocal microscopy images, after 1 h incubation at 10 μM concentration, HBHAc-EGFP treated cells showed obvious green fluorescence in the cytoplasm and barely detectable signals were observed in the EGFP treated cells. Furthermore, the transduction of HBHAc-EGFP occurred rapidly and the mean fluorescence intensity gradually intensified until about 1 h of incubation based on the results of flow cytometry and confocal microscopy. However, the mean fluorescence intensity decreased significantly after 2 h incubation. According to the results of immunofluorescence assay, the internalized HBHAc-EGFP was co-localized with early endosome antigen-1 (EEA1) but was not co-localized with caveolin-1. In the endolyosomal blockade assay, HepG2 cells were treated with HBHAc-EGFP and chloroquine for 1 h and replaced with new medium with chloroquine for a period of time. The mean fluorescence intensity measured by flow cyometry remained until 12 h in chloroquine treated cells but dropped dramatically within 1 h in non-chloroquine treated cells. It suggests that chloroquine could effectively block the endolysosomal degradation of HBHAc-EGFP in HepG2 cells. Furthermore, the cellular uptake of HBHAc-EGFP was significantly decreased when cells were incubated at 4℃ or 16℃. In the endocytosis inhibition assay, the entry of HBHAc-EGFP was inhibited by 40% in chlorpromazine treated cells, and methyl-β-cyclodextrin and amiloride only showed about 20% of inhibition. Besides, membrane competitors, heparin and dextran sulfate, greatly reduced the internalization of HBHAc-EGFP up to 90%. These results suggest that the internalization of HBHAc-EGFP fusion protein in HepG2 cells is mostly via clathrin-mediated endocytosis through interaction with heparan sulfate proteoglycans on the plasma membrane. Furthermore, most internalized HBHAc-EGFP was distributed in the endosome and degraded through endolysosmal pathway. However, our previous study showed that HBHAc may utilize direct transduction or lipid-raft endocytosis. In addition, membrane interaction competitors inhibit the cellular uptake of HBHAc-EGFP more effectively than the cellular uptake of HBHAc. HBHAc can effectively deliver EGFP into cells without disrupting the activity of EGFP and no obvious cytototoxicity was observed at the concentrations used for delivering EGFP. Due to the degradation of HBHAc-EGFP by endolysosomal pathway, appropriate endosomal escape strategies are needed for HBHAc to be used as a potiential protein carrier. | en |
dc.description.provenance | Made available in DSpace on 2021-06-07T17:51:12Z (GMT). No. of bitstreams: 1 ntu-101-R99423018-1.pdf: 3892801 bytes, checksum: 00bce8b933753017d9beaed742f9ab5a (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 目錄
圖目錄 IV 表目錄 VI 附錄目錄 VII 第一章 緒論 1 1.1 蛋白質藥物的發展與遞輸 1 1.2 細胞穿透胜肽 (cell-penetrating peptide, CPPs) 2 1.2.1 背景與分類 3 1.2.2 細胞內化途徑與機轉 4 1.2.3 細胞穿透胜肽作為遞輸載體的應用與限制 7 1.3 肝素結合凝血附著素 (heparin-binding haemagglutinin adhesin,HBHA) 9 1.3.1 HBHA蛋白的功能與特性 9 1.3.2 HBHA蛋白C端序列片段的研究 10 1.3.3 HBHA蛋白C端相關胜肽片段的穿膜 (membrane transduction) 特性 11 1.4 綠色螢光蛋白 (Green fluorescence protein) 12 1.4.1 綠色螢光蛋白的發現與應用 12 1.4.2 綠色螢光蛋白的結構與發光原理 13 1.4.3 綠色螢光蛋白用於細胞穿透胜肽的研究 14 第二章 實驗目的 16 第三章 實驗材料與方法 18 3.1 實驗材料 18 3.2 細胞培養 (Cell culture) 23 3.3 重組DNA質體 (Construct HBHAc-EGFP and EGFP expression plasmid) 24 3.3.1 製備EGFP-6xHistidine基因序列片段 24 3.3.2 製備插入DNA片段 (insert DNA) 25 3.3.3 製備表現載體DNA片段 (vector DNA) 26 3.3.4 黏合插入與載體DNA片段 (DNA ligation) 26 3.4 重組蛋白表現與純化 (Expression and purification of recombinant proteins) 28 3.4.1 重組蛋白表現 28 3.4.2 重組蛋白純化 29 3.4.3 重組蛋白的濃度測定 (BCA assay) 29 3.4.4 重組蛋白的純度分析 30 3.5 細胞存活率試驗 (Cell viability assay) 31 3.6 細胞攝取動力學分析 (Kinetics of cellular uptake assay) 32 3.6.1 流式細胞儀分析 (Flow cytometry analysis) 32 3.6.2 共軛焦螢光影像分析 (Confocal microscopy analysis) 33 3.7 細胞內分布分析 (The investigation of intracellular distribution) 34 3.7.1 Endolysosomal blockade assay 34 3.7.2 免疫螢光染色影像分析 (Immunofluorescence assay) 35 3.8 細胞攝取機轉分析 (The analysis of cellular uptake mechanism) 36 3.8.1 溫度性試驗 (Temperature-dependent assay) 37 3.8.2 胞吞作用抑制性試驗 (Endocytosis inhibition assay) 37 3.8.3 膜作用競爭性試驗 (Membrane interaction competition assay) 38 3.9 統計分析 38 第四章 實驗結果 40 4.1 表現質體的製備與重組蛋白的純化 40 4.2 重組蛋白對細胞的的毒性試驗 41 4.3 HBHAc-EGFP進入細胞的效率分析 42 4.4 HBHAc-EGFP在細胞內的分布與降解途徑 45 4.5 HBHAc-EGFP穿透細胞膜與溫度的相關性 49 4.6 HBHAc-EGFP被細胞攝取的相關胞吞作用途徑分析 51 4.7 HBHAc-EGFP與細胞膜上醣蛋白的相互作用分析 52 第五章 討論 55 5.1 HBHAc-EGFP對HepG2細胞不具有細胞毒性 55 5.2 HBHAc遞送EGFP進入HepG2細胞的效率與胞內的安定性 56 5.3 HBHAc-EGFP在細胞內的分布途徑 59 5.4 HBHAc-EGFP的細胞攝取機轉 61 5.5 HBHAc作為蛋白質藥物遞送載體的發展 67 5.6 本研究之實驗限制 68 第六章 結論 70 第七章 參考文獻 125 | |
dc.language.iso | zh-TW | |
dc.title | 含穿胞胜肽HBHAc之重組綠色螢光蛋白於肝癌細胞株的胞內運輸之研究 | zh_TW |
dc.title | Study on the ability and mechanism of intracellular delivery of a recombinant enhanced green fluorescence protein(EGFP)fused with a cell-penetrating peptide, HBHAc, in a hepatocellular carcinoma cell line | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林文貞(Wen-Jen Lin),許麗卿(Lih-Ching Hsu),孔繁璐(Fan-Lu Kung) | |
dc.subject.keyword | 肝素結合凝血附著素,細胞穿透胜肽,綠色螢光蛋白,蛋白質胞內遞送,胞噬作用, | zh_TW |
dc.subject.keyword | heparin-binding haemaglutinin adhesin,cell-penetrating peptide,green fluorescence protein,protein delivery,endocytosis, | en |
dc.relation.page | 140 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2012-10-02 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 3.8 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。